Hansoh Pharmaceutical's Lenalidomide Capsules Approved for Market Launch in China

On April 1, Hansoh Pharma (03692) announced that its “Lenalidomide Capsules,” developed by its subsidiary Jiangsu Hansoh Pharmaceutical Group Co., Ltd., had received drug registration approval from the National Medical Products Administration of the People’s Republic of China.

This product is an antineoplastic agent indicated for the treatment of adult patients with multiple myeloma in combination with dexamethasone, specifically for those who are newly diagnosed and ineligible for transplantation, as well as for those who have received at least one prior therapy. The approval of this product’s drug registration will further enrich and enhance the Group’s oncology product portfolio.

Responsible Editor: Liu Li

Disclaimer: This article is reproduced from Yaozhi.com. The copyright belongs to the original author. The purpose of this reproduction is to convey more information, and it does not represent the views of this platform. If there are any issues regarding the content, copyright, or other matters, please leave a message on our website, and we will remove the content promptly.